Recent studies have reported increased nevirapine hepatotoxicity in female patients with CD4 lymphocyte counts greater than 250 cells/μl (especially pregnant women). However, our open-label comparison of 742 patients treated with either nevirapine or efavirenz-based HAART as naive patients, experienced subjects, or patients on salvage therapy, found no increased hepatotoxicity in nevirapine-treated subjects, in particular with regard to both sex (females versus males) and T-cell-mediated immunodeficiency (CD4 cell counts above versus below 250 cells/μl).
Department of Clinical and Experimental Medicine, Division of Infectious Diseases, ‘Alma Mater Studiorum’ University of Bologna, S. Orsola-Malpighi Hospital, Bologna, Italy
Received 28 July, 2006
Accepted 19 September, 2006